The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Heart failure affects an estimated 64.3 million people worldwide
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Subscribe To Our Newsletter & Stay Updated
